Stockholders Equity (Tables)
|
12 Months Ended |
Dec. 31, 2021 |
|---|
| Stockholders Equity (Tables) [Line Items] |
|
| Schedule of outstanding warrants |
| Warrant |
|
Issuance
Date |
|
Expiration
Date |
|
Exercise
Price
Per Share |
|
|
Number
of
Shares of
Common Stock
Underlying
Warrants |
|
| Private Placement
Warrants |
|
IPO (December 13, 2018) |
|
December 13, 2023 |
|
|
11.50 |
|
|
|
2,900,000 |
|
| Public Warrants |
|
IPO (December 13, 2018) |
|
October 28, 2024 |
|
|
11.50 |
|
|
|
3,500,000 |
|
| 2021 Registered Direct
Offering Warrants |
|
SPA (July 28, 2021) |
|
January 28, 2027 |
|
|
5.00 |
|
|
|
2,812,501 |
|
| |
|
|
|
|
|
|
|
|
|
|
9,212,501 |
|
|
| Schedule of black-scholes option-pricing model |
| |
|
2021 |
|
|
2020 |
|
| |
|
|
|
|
|
|
| Underlying value of Common Stock ($) |
|
|
7.02 |
|
|
|
5.59-6.44 |
|
| Exercise price ($) |
|
|
7.02 |
|
|
|
5.59-6.44 |
|
| Expected volatility (%) |
|
|
85.0 |
|
|
|
85.0 |
|
| Expected terms of the option (years) |
|
|
6.11 |
|
|
|
6.11 |
|
| Risk-free interest rate (%) |
|
|
1.17 |
|
|
|
0.39-0.68 |
|
|
| Schedule of options granted to purchase common stock |
| |
|
For year ended
December 31, 2021 |
|
| |
|
Number of
Options |
|
|
Weighted
average
exercise
price |
|
|
Aggregate
intrinsic
value |
|
| |
|
|
|
|
|
|
|
|
|
| Outstanding at the beginning of period |
|
|
3,569,766 |
|
|
$ |
3.12 |
|
|
$ |
12,338 |
|
| Granted |
|
|
985,530 |
|
|
|
7.02 |
|
|
|
|
|
| Forfeited |
|
|
(386,508 |
) |
|
|
4.60 |
|
|
|
|
|
| Exercised |
|
|
(84,239 |
) |
|
$ |
1.55 |
|
|
|
|
|
| Outstanding at the end of period |
|
|
4,084,549 |
|
|
|
3.95 |
|
|
$ |
671 |
|
| Vested at end of period |
|
|
2,486,381 |
|
|
|
|
|
|
|
|
|
| Weighted average remaining contractual life – years as of December 31, 2021 |
|
|
6.82 |
|
|
|
|
|
|
|
|
|
| |
|
For year ended
December 31, 2020 |
|
| |
|
Number of
Options |
|
|
Weighted
average
exercise
price |
|
|
Aggregate
intrinsic
value |
|
| |
|
|
|
|
|
|
|
|
|
| Outstanding at the beginning of period |
|
|
3,143,802 |
|
|
$ |
1.61 |
|
|
$ |
25,733 |
|
| Granted |
|
|
925,700 |
|
|
|
6.17 |
|
|
|
|
|
| Forfeited |
|
|
(108,110 |
) |
|
|
4.66 |
|
|
|
|
|
| Exercised |
|
|
(391,626 |
) |
|
$ |
0.79 |
|
|
|
|
|
| Outstanding at the end of period |
|
|
3,569,766 |
|
|
$ |
3.12 |
|
|
$ |
12,338 |
|
| Vested at end of period |
|
|
2,334,037 |
|
|
|
|
|
|
|
|
|
| Weighted average remaining contractual life – years as of December 31, 2020 |
|
|
7.62 |
|
|
|
|
|
|
|
|
|
|
| Schedule of share-based payment expenses |
| |
|
Year ended
December 31, |
|
| |
|
2021 |
|
|
2020 |
|
| |
|
|
|
|
|
|
| Research and development expenses, net |
|
|
1,770 |
|
|
|
1,815 |
|
| General and administrative |
|
|
1,467 |
|
|
|
1,075 |
|
| |
|
|
3,237 |
|
|
|
2,890 |
|
|
| Warrant [Member] |
|
| Stockholders Equity (Tables) [Line Items] |
|
| Schedule of outstanding warrants |
| Warrant |
|
Issuance
Date |
|
Expiration
Date |
|
Exercise
Price
Per Share |
|
|
Number
of
Shares of
Common Stock
Underlying
Warrants |
|
| Private Warrants issued to Yeda (see 1 below) |
|
May 11, 2017 |
|
May 11, 2025 |
|
|
(* |
) |
|
|
-
|
|
| Private Warrants issued to scientific
founders (see 2 below) |
|
November 27, 2017 |
|
|
|
|
- |
|
|
|
2,974 |
|
| |
|
|
|
|
|
|
|
|
|
|
2,974 |
|
|